Tranexamic acid is cheap, shelf-stable, and now standard in many trauma and postpartum-hemorrhage protocols. But the benefit only holds if we give it early — and there is evidence of harm if we give it late.
The Cheapest Drug on the Truck That Actually Changes Outcomes
We carry a lot of expensive equipment. Tranexamic acid (TXA) is not one of them — a gram costs a few dollars, sits at room temperature, and has a multi-year shelf life. What it buys us, given correctly, is a measurable drop in death from hemorrhage. The catch is that "correctly" is mostly about the clock.
How TXA Actually Works
TXA is a synthetic lysine analog. It works by competitively binding the lysine-binding sites on plasminogen, blocking its conversion to plasmin. Plasmin is the enzyme that breaks down fibrin — so by inhibiting that step, TXA slows fibrinolysis and helps the clots we are forming stay formed.
This matters because severe trauma drives a hyperfibrinolytic state: the body starts dissolving its own clots at the worst possible moment. TXA is one of the few field interventions that directly attacks one leg of the lethal triad we treat with whole blood and active warming.
Dose and the 3-Hour Window
The dosing most systems use traces back to the CRASH-2 trial: 1 g IV over roughly 10 minutes, followed by 1 g infused over 8 hours. Many EMS protocols give the 1 g bolus in the field and let the receiving facility run the maintenance dose. For postpartum hemorrhage, the WOMAN trial supports a 1 g IV dose.
The non-negotiable detail is timing:
- Give it early. The mortality benefit is concentrated when TXA is administered within 3 hours of injury.
- The clock starts at injury, not at IV access. A 3-hour-old GSW that you just reached does not reset because you only now have a line.
- Late dosing can hurt. The trial data show that giving TXA after the 3-hour mark is associated with *increased* mortality from bleeding, not benefit.
Field Practicalities and the Error We Keep Making
- Push it slow. Rapid IV administration is associated with transient hypotension. Dilute the bolus and run it over about 10 minutes rather than slamming it.
- Seizure risk rises at high cumulative doses — relevant in the hospital phase more than the single field gram, but worth knowing.
- Wrong-route deaths are real. TXA ampoules have been confused with local anesthetics and other drugs, with fatal intrathecal administration reported. Read the label twice.
- Logistics win: unlike blood, TXA needs no cold chain. That makes it realistic to stock on nearly every unit, including BLS-adjacent first-response bags where protocols allow.
| TXA | Whole Blood (LTOWB) | Crystalloid | |
|---|---|---|---|
| What it does | Stops clot breakdown | Replaces oxygen carriers + clotting factors | Volume only |
| Replaces blood? | No | Yes | No |
| Cold chain? | None — room temp | 1–6°C | None |
| Shelf life | Years | ~35 days | Years |
| Time-critical? | Yes — under 3 hrs | Earlier is better | Dilutes clotting factors |
The takeaway for the field: TXA does not replace blood, and it does not replace controlling the bleeding. It is an early, time-boxed adjunct that is most useful in the first hour — exactly the window we own. A clean, time-stamped drug log on every push is what lets the trauma team know precisely where in that window the patient sits.
Curated by Jonathan B
Tracking the tools of tomorrow